Search Results for “EC” – Page 115 – media

Biden administration declares fentanyl laced with xylazine ‘an emerging threat’ in the US

By Jacqueline Howard, CNN Updated 2:41 PM EDT, Wed April 12, 2023 The White House has declared that the powerful synthetic opioid fentanyl combined with xylazine – an animal tranquilizer that’s increasingly being used in illicit drugs – is an “emerging threat” facing the United States due to its role in the ongoing opioid crisis. Administration officials call the threat FAAX, for fentanyl-adulterated or -associated xylazine. The move, announced Wednesday, marks the first time in history that any administration has declared a substance to be an emerging threat to the country, said Dr. Rahul Gupta, director of the Office of National Drug Control Policy. The SUPPORT Act of 2018 established that the office has authority to declare such “emerging threats,” and no administration has used it until now. Last year, Congress declared methamphetamine an emerging drug threat but none have been declared by an administration previously. Under other agencies or in separate circumstances, concerns such as bioterrorism, ...
- Source: drugdu
- 124
- April 13, 2023
‘This Is a First’

Marcia Frellick April 07, 2023 Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Researchers have found for the first time that COVID infection has crossed the placenta and caused brain damage in two newborns, according to a study published online today in Pediatrics. One of the infants died at 13 months and the other remained in hospice care at time of manuscript submission. Lead author Merline Benny, MD, with the division of neonatology, department of pediatrics at University of Miami, and colleagues briefed reporters today ahead of the release. “This is a first,” said senior author Shahnaz Duara, MD, medical director of the Neonatal Intensive Care Unit at Holtz Children’s Hospital, Miami, explaining it is the first study to confirm cross-placental SARS-CoV-2 transmission leading to brain injury in a newborn. Both infants negative for the virus at birth ...
- Source: drugdu
- 145
- April 12, 2023
Pfizer and Moderna’s COVID-19 vaccines offer lasting protection

Study finds on April 7th, 2023, Pharmaceutical Technology reported that a new study has found that Pfizer and Moderna’s COVID-19 vaccines offer lasting protection against the virus. The study, which was published in the New England Journal of Medicine, found that people who received either vaccine had robust and persistent antibody and T cell responses against SARS-CoV-2, the virus that causes COVID-19, even six months after receiving the second dose. The study followed 2,500 healthcare workers who received either the Pfizer or Moderna vaccine and found that their immune responses remained strong over time. The researchers noted that while antibody levels did decline over time, the levels were still high enough to provide protection against the virus. The findings are significant because they suggest that the vaccines are likely to provide long-term protection against COVID-19. The study also provides reassurance that the vaccines are effective against new variants of ...
- Source: drugdu
- 172
- April 12, 2023
New study shows SARS-CoV-2 infection accelerates the progression of dementia

The possible common pathomechanisms linking multiple sclerosis and post-COVID-19 brain involvement (A). Proposal of a new codename regarding post-COVID-19 cognitive sequelae (B). Credit: Journal of Alzheimer’s Disease Reports (2023). DOI: 10.3233/ADR-220090 Infection with SARS-CoV-2 has a significant impact on cognitive function in patients with preexisting dementia, according to new research published in the Journal of Alzheimer’s Disease Reports. Patients with all subtypes of dementia included in the study experienced rapidly progressive dementia following infection with SARS-CoV-2. Since the first wave of COVID-19, neurologists have noticed both acute and long-term neurological syndromes and neuropsychiatric sequelae of this infectious disease. Insights into the impact of COVID-19 on human cognition has so far remained unclear, with neurologists referring to “brain fog.” A group of researchers driven to gain a better understanding of and dissipate this fog investigated the effects of COVID-19 on cognitive impairment in 14 patients with preexisting dementia (four with Alzheimer’s disease [AD], five with vascular dementia, three ...
- Source: drugdu
- 158
- April 7, 2023
Mediterranean diet linked to greater biodiversity and food security, study finds

Dr. Priyom Bose, Ph.D. By Dr. Priyom Bose, Ph.D.Apr 5 2023 Reviewed by Danielle Ellis, B.Sc. To combat the double burden of non-communicable diseases and climate change, adopting sustainable and healthy diets and transitioning to sustainable food systems is essential. To support food security and sustainable development, the Mediterranean diet (MD) has been widely recognized as a healthy nutrition and biodiversity resource. A recent Advances in Nutrition study explored biodiversity and analyzed food-plant diversity differences between the Western diet and the MD. Background The global population is expected to rise to 10.9 billion by the end of the century. The Food and Agriculture Organization (FAO) estimates that food production must increase by almost 50% to meet consumers’ demands. Rapid population growth is often considered a threat to sustainable development, as it stresses natural resources. The existing agro-food system has also been cited as a key driver of climate change and environmental ...
- Source: drugdu
- 162
- April 6, 2023
GSK will have to pay additional royalties to AstraZeneca on cancer drug Zejula

[GSK already has concerns with cancer drug Zejula, which is under scrutiny as a member of the PARP inhibitor class. Not the company has taken a loss in court as it will have to surrender added royalties to AstraZeneca for the drug which rolled up sales of 463 pound sterling ($571 million) last year. (GSK)] When Emma Walmsley took over as CEO at GSK in 2017, one of her first moves was to beef up the company’s oncology portfolio with a $5.1 billion acquisition of cancer specialist Tesaro and its newly approved drug Zejula. The ovarian cancer treatment generated 463 pound sterling ($571 million) in 2022, representing a 17% increase from the previous year. So far, so good, right? Well, not exactly. After losing a patent case in court on Wednesday, GSK will have to surrender a portion of its sales of Zejula to Tesaro’s partner on ...
- Source: drugdu
- 152
- April 6, 2023
SARS-CoV-2 infection weakens immune-cell response to vaccination

Colorized scanning electron micrograph of a cell (red) infected with the Omicron strain of SARS-CoV-2 virus particles (blue), isolated from a patient sample.NIAID The magnitude and quality of a key immune cell’s response to vaccination with two doses of the Pfizer-BioNTech COVID-19 vaccine were considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, a study has found. In addition, the level of this key immune cell that targets the SARS-CoV-2 spike protein was substantially lower in unvaccinated people with COVID-19 than in vaccinated people who had never been infected. Importantly, people who recover from SARS-CoV-2 infection and then get vaccinated are more protected than people who are unvaccinated. These findings, which suggest that the virus damages an important immune-cell response, were published today in the journal Immunity. The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National ...
- Source: drugdu
- 128
- April 6, 2023
One in six people worldwide affected by infertility, WHO reports

One in six people worldwide are affected by infertility, according to a report that lays bare the scale of the problem. About 17.5% of the global adult population – roughly one in six – will experience infertility at some point in their lifetime, the 98-page report published by the World Health Organization (WHO) says. The figures are its first estimates of infertility prevalence in more than a decade. Dr Tedros Adhanom Ghebreyesus, the WHO director general, said the report underlined the magnitude of infertility as a public health issue globally, and showed there was an urgent need to expand access to prevention, diagnosis and treatments. “The report reveals an important truth – infertility does not discriminate,” said Tedros. “The sheer proportion of people affected shows the need to widen access to fertility care and ensure this issue is no longer sidelined in health research and policy, so that safe, effective and affordable ...
- Source: drugdu
- 221
- April 6, 2023
Direct Acting Antiviral Drugs For The Treatment Of Hepatitis C

This is fourth installment in my series on progress toward the elimination of Hepatitis C infection and disease. Read more about Hepatitis C in part one, part two and part three. Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A … [+] In the previous articles of this series, I’ve outlined the seriousness and uncontrolled nature of hepatitis C. In the absence of a vaccine, the control and treatment of hepatitis C, much like that of HIV/AIDS, depends on the use of antiviral medications. Recent progress in the development of several highly active, anti-hepatitis C drugs has been a triumph of modern medicine. These drugs usher in an era of effective treatment and even elimination of hepatitis C both nationally and globally. Later in this series I will describe how these drugs have been used to eliminate hepatitis C from some countries and discuss how that success may be ...
- Source: drugdu
- 260
- April 4, 2023
In $2.6B cell and gene therapy expansion, Sartorius buys viral vector specialist Polyplus

[Before the Sartorius buyout, Polyplus had itself been expanding through multiple acquisitions. (Sartorius)] As the biopharma industry struggles with a dire shortage of viral vectors to make cell and gene therapies, contract manufacturers are busy beefing up their capabilities. In the latest example of biopharma’s ongoing investment in cell and gene therapy production, Sartorius has agreed to acquire French company Polyplus for 2.4 billion euros ($2.6 billion), the German CDMO said Friday. The deal gives Sartorius additional know-how in nucleic acid delivery, including transfection reagents and plasmid DNA design, all of which are key elements in the production of viral vectors for building cell and gene therapies. Formed in 2001, Polyplus employs about 270 people in several locations in France, Belgium, the U.S. and China. Before the Sartorius buyout, Polyplus had itself been expanding through M&A deals. In 2021, Polyplus bought Asia-Pacific-focused reagent supplier Biowire. ...
- Source: drugdu
- 267
- April 4, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.